ArticleOncotarget2017
The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Ahmed glaucoma valve implantation with and without subconjunctival bevacizumab in refractory glaucoma.International ophthalmology · 2021Trial
- Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer.BMC medical research methodology · 2021Trial
- MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.Targeted oncology · 2019Trial
- New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Current treatment options in oncology · 2023Review
- Article
- Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer.JAMA network open · 2023Article
- Article
- Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.Communications biology · 2020Article
- Article
- Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy.Oncology letters · 2019Article
- Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy.World journal of clinical oncology · 2019Review
- Neoadjuvant Chemotherapy Alters Neuropilin-1, PlGF, andFrontiers in oncology · 2019Article
- Targeting Angiogenesis in Colorectal Carcinoma.Drugs · 2019Review
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Clinical pharmacokinetics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab has shown survival benefits when added to chemotherapy in patients with metastatic colon cancer (mCRC). However, the efficacy of bevacizumab may depend on the accompanying chemotherapeutic regimen. We performed this meta-analysis to examine the impact of the choice of chemotherapy regimen on the survival benefits of bevacizumab in the first-line treatment for patients with mCRC. Electric databases were searched for eligible randomized trials. From 9 studies, 3,710 patients with mCRC were included in the meta-analysis of hazard ratios (HRs) for progression-free survival (PFS) or overall survival (OS). Compared with chemotherapy alone, the addition of bevacizumab to chemotherapy significantly prolonged PFS (HR = 0.66 [95% confidence interval (CI), 0.55-0.77],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.